1. Stats
  2. USPTO
  3. TC 1600
  4. Group 1620
  5. Art Unit 1623
  6. Examiner Shterengarts

Examiner Shterengarts Samantha L

1623-SHTERENGARTS-SAMANTHA-L

Employment Information

Art Unit:1623 — Drug, bio-affecting and body treating compositions
Group:1620 — Biomedicinal Chemistry
Classes: 514 — Drug, bio-affecting and body treating compositions
548 — Organic compounds -- part of the class 532-570 series
544 — Organic compounds -- part of the class 532-570 series
549 — Organic compounds -- part of the class 532-570 series
558 — Organic compounds -- part of the class 532-570 series
424 — Drug, bio-affecting and body treating compositions
546 — Organic compounds -- part of the class 532-570 series
540 — Organic compounds -- part of the class 532-570 series
435 — Chemistry: molecular biology and microbiology
534 — Organic compounds -- part of the class 532-570 series
Phone:(571) 270-5316
Email:samantha.shterengarts@uspto.gov
Location:VA 22314
Title:Pat Examnr Gen Chem
Service:18 years
Grade:GS-14

Grant Rate and Difficulty Ranking

48
3-Year Grant rate: 79% over 751 cases
Difficulty: Medium
Difficulty Percentile: 48th

With Examiner Shterengarts, you have a 79% chance of getting an issued patent by 3 years after the first office action. Examiner Shterengarts is a medium examiner and in the 48th percentile across all examiners (with 100th percentile most difficult).

Grant Rate

Grant Rate Timeline

Below is the grant rate timeline for Examiner Shterengarts, where the timeline is relative to the date of the first office action. The three-year grant rate is the percentage of applications granted at three years after the first office action.

Comparison with Art Unit 1623

Examiner Shterengarts's grant rate is higher than that of Art Unit 1623 and higher than that of the USPTO.

Average Office Actions Per Grant
Examiner Shterengarts 1.3
Art Unit 1623 1.5

Interview Benefit

Grant Rate without Interview

Examiner Shterengarts has granted 577 of 734 cases without any applicant-requested interviews for a grant rate of 79%.

Grant Rate with Interview

Examiner Shterengarts has granted 15 of 17 cases with at least one applicant-requested interview for a grant rate of 88%.

Interview Benefit

With Examiner Shterengarts, conducting an interview increases your chance of getting a patent granted by 11%.

Recent Dispositions

Recent Dispositions

Number Title OA Rejections Status IFW
18549188 Thiophene Compound And Application Thereof Rejection information available with a Premium Stats subscription. See our pricing. Abandoned View
18259089 Novel Method For Synthesizing Nca Compounds Abandoned View
18531320 Manufacture Of Compounds And Compositions For Inhibiting The Activity Of Shp2 Abandoned View
18374282 Bifunctional Compounds For Degrading Btk Via Ubiquitin Proteosome Pathway Patented View
18605319 Remodilins To Prevent Or Treat Cancer Metastasis, Glaucoma, And Hypoxia Abandoned View
18043087 Process For The Preparation Of 2,2-Difluoro-1,3-Benzodioxole Derivatives With Sulfur Containing Substituents Abandoned View
17632985 Molecular Complexes Abandoned View
17750560 Dna Primase And Gyrase Inhibitors Abandoned View
17774843 Functionally Modified Maytansinoids And Compositions And Methods Of Use Thereof Patented View
18305688 Androgen Receptor Modulators And Methods For Their Use Abandoned View
18272465 Composition Comprising (7s)-(+)-Cyclopentyl Carbarmic Acid, 8,8-Dimethyl-2-Oxo-6,7-Dihydro-2h,8h-Pyrano[3,2-G]chromen-7-Yl-Ester As Active Ingredient For Prevention, Alleviation, Or Treatment Of Eye Disease Patented View
18271162 Pyridone Multiple-Membered Ring Derivatives And Use Thereof Patented View
18342064 Fluorescent Dyes Containing Fused Tetracyclic Bis-Boron Heterocycle And Uses In Sequencing Patented View
18257133 Preparation Of Tetrahydroindazole Derivatives As Novel Diacylglyceride O-Acyltransferase 2 Inhibitors Patented View
18272439 Tryptamine Analogues Patented View
17755946 Biotin-Containing Monomers And Articles Formed Therefrom Patented View
18363661 Processes For Preparing A Mdm2 Inhibitor Patented View
18202812 Pegylated Menaquinol Compositions And Methods Of Treatment Patented View
17935949 Gaba Complex Composition Patented View
18261363 Method For Purifying Key Intermediates Of Citalopram Patented View
18529485 Tetrazole Derivatives As Trpa1 Inhibitors Abandoned View
17055602 Compositions Comprising Bisfluoroalkyl-1,4-Benzodiazepinone Compounds And Methods Of Use Thereof Abandoned View
18778172 Glun2b-Subunit Selective Antagonists Of The N-Methyl-D-Aspartate Receptors With Enhanced Potency At Acidic Ph Patented View
18097640 Substituted Imidazole Salt Compounds, Preparation Method Thereof, Pharmaceutical Composition Thereof And Application Thereof Patented View
18330978 Methods And Compounds For Restoring Mutant P53 Function Abandoned View
18497891 Modulators Of Mas-Related G-Protein Receptor X4 And Related Products And Methods Abandoned View
18428316 Cd73 Compounds Abandoned View
17457733 Fused Thiophene Compounds Abandoned View
18477050 Glp-1 Receptor Agonists And Uses Thereof Patented View
17613910 Methyl- And Trifluoromethyl-Containing Disubstituted Sulfonamide Selective Bcl-2 Inhibitor Patented View
17618878 Compounds For Modulating Fxr Abandoned View
17596353 Improved Methods For Converting Cannabidiol Into Delta9-Tetrahydrocannabinol Under Protic Reaction Conditions Abandoned View
17608434 Compounds And Methods For Treating Cancer Patented View
18427164 Rad51 Inhibitors Abandoned View
17605170 Meloxicam Co-Crystal Compositions Abandoned View
18464646 Pharmaceutical Formulations Comprising A Pyridylaminoacetic Acid Compound Patented View
18448277 Thyroid Hormone Receptor Agonists And Use Thereof Patented View
17730112 Indazole Compounds As Mglur4 Allosteric Potentiators, Compositions, And Methods Of Treating Neurological Dysfunction Patented View
17041703 Combination Comprising Hdac Inhibitor And Cd137 Agonist For Cancer Therapy Patented View
18373702 Compounds And Uses Thereof Patented View
18057742 Therapeutic Compounds And Methods Of Use Patented View
17283441 Azaindole Inhibitors Of Wild-Type And Mutant Forms Of Lrrk2 Patented View
18405058 Delivery Of Therapeutic Alkaloid Compounds Patented View
18361558 Hydrophilic Antibody-Drug Conjugates Patented View
18491021 N-(Hydroxyalkyl (Hetero)aryl) Tetrahydrofuran Carboxamides As Modulators Of Sodium Channels Patented View
18463707 Methods And Pharmaceutical Compositions For The Treatment Of Fgfr3-Related Chondrodysplasias Patented View
17055550 Fatty Acid Analogues And Methods Of Use Patented View
18504672 Deuterated Compounds And Uses Thereof Patented View
17633151 Cyclobutyl Dihydroquinoline Sulfonamide Compounds Patented View
18463878 Phosphine Reagents For Azine Fluoroalkylation Abandoned View

Appeals Statistics

Purchase Subscription

Subscribe to Premium Examiner Statistics for unlimited access for your law firm.

Disclaimer: We do not provide any guarantees as to the accuracy of the statistics presented above and under
no circumstances will we be liable for any outcome resulting from your reliance on the above statistics.